Method and apparatus for the measurement of autonomic function for the diagnosis and validation of patient treatments and outcomes

What is this patent about?

’203 is related to the field of bioanalytical analysis and medical diagnostics, specifically focusing on the objective quantification of pain. Traditionally, pain assessment has relied on subjective self-reporting, such as the Visual Analog Scale, which is prone to inconsistency and communication barriers. This invention provides a technical framework for measuring physiological responses within the autonomic nervous system to validate health status and treatment efficacy.

The underlying idea behind ’203 is that pain is not merely a subjective feeling but a measurable neurological event reflected in the pain matrix of the brain. By capturing electrical biosignals across the body’s midline, the system identifies asymmetries in electrodermal activity that correlate with central nervous system distress. The core engineering insight involves using these physiological deflections to bypass verbal reporting, providing a data-driven baseline for clinical decision-making.

The claims of ’203 focus on a specialized sensor configuration and a multi-factor data processing architecture. The system utilizes a contralateral sensor set to detect voltage or current differentials across the body, supplemented by at least one ipsilateral sensor used specifically for calibration and normalization of the primary biosignal. This hardware arrangement is integrated with a networked processor that correlates these real-time signals with a library of biopsychosocial variables known as BioTrace Factors.

In practice, the system functions by establishing a baseline through standardized noxious stimuli and then monitoring for signal deflections that indicate changes in pain intensity. The controller processes the raw electrical data by comparing the individual’s profile against a similarly situated population to account for demographic and environmental variables. This allows the system to differentiate between actual physiological pain and other autonomic responses like stress or anxiety, which might otherwise skew the data.

This approach differs from prior art by moving beyond simple galvanic skin response or heart rate monitoring to a holistic bioanalytical analysis that integrates clinical outcomes with longitudinal data. By combining objective biosignal measurements with historical treatment efficacy and demographic modeling, the invention provides a closed-loop system for adjusting medication dosages and validating recovery. This integration helps prevent opioid mismanagement and provides a verifiable metric for patient compliance and treatment success.